**Core Concept**
The Multiple Endocrine Neoplasia (MEN) syndrome is a group of autosomal dominant disorders characterized by the occurrence of tumors in multiple endocrine glands, including the pancreas, parathyroid glands, and adrenal glands. The syndrome is associated with an increased risk of developing various types of endocrine tumors, including pancreatic neuroendocrine tumors (PNETs).

**Why the Correct Answer is Right**
The sulfonylureas, such as **Option A: Glimepiride**, are a class of antidiabetic drugs that stimulate insulin release from the pancreatic beta cells. However, patients with MEN syndrome are at increased risk of developing PNETs, which can be malignant and produce excess insulin, leading to hypoglycemia. The use of sulfonylureas in these patients can exacerbate hypoglycemia and worsen the clinical outcome.

**Why Each Wrong Option is Incorrect**
* **Option B: Metformin** is a biguanide antidiabetic drug that works by decreasing glucose production in the liver and increasing insulin sensitivity. It is not contraindicated in patients with MEN syndrome.
* **Option C: Pioglitazone** is a thiazolidinedione antidiabetic drug that works by increasing insulin sensitivity. It is not contraindicated in patients with MEN syndrome.
* **Option D: Sitagliptin** is a dipeptidyl peptidase-4 (DPP-4) inhibitor antidiabetic drug that works by increasing the levels of incretin hormones, which stimulate insulin release. It is not contraindicated in patients with MEN syndrome.

**Clinical Pearl / High-Yield Fact**
Patients with MEN syndrome require careful management of their endocrine tumors and are at increased risk of developing hypoglycemia due to excess insulin production. The use of sulfonylureas in these patients can worsen hypoglycemia and clinical outcome.

**Correct Answer:** A. Glimepiride